Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Preferred Stock Liabilities (2019)

Historic Preferred Stock Liabilities for Avidity Biosciences (RNA) over the last 1 years, with Q4 2019 value amounting to $134.7 million.

  • Avidity Biosciences' Preferred Stock Liabilities changed N/A to $134.7 million in Q4 2019 from the same period last year, while for Dec 2019 it was $134.7 million, marking a year-over-year change of. This contributed to the annual value of $134.7 million for FY2019, which is N/A changed from last year.
  • As of Q4 2019, Avidity Biosciences' Preferred Stock Liabilities stood at $134.7 million.
  • Over the past 5 years, Avidity Biosciences' Preferred Stock Liabilities peaked at $134.7 million during Q4 2019, and registered a low of $134.7 million during Q4 2019.